nicotinamide mononucleotide + radiotherapy + PD-1 inhibitor

Nicotinamide mononucleotide + radiotherapy + PD-1 inhibitor is a combination therapeutic regimen being investigated by Sichuan University (West China Hospital) for the treatment of advanced non-small cell lung cancer (NSCLC). The regimen integrates the dietary supplement nicotinamide mononucleotide (NMN), which serves as a precursor to nicotinamide adenine dinucleotide (NAD+), with standard-of-care radiotherapy and a programmed cell death protein 1 (PD-1) inhibitor. The rationale for this combination is that NMN may enhance the efficacy of radioimmunotherapy by modulating cellular metabolism and the immune microenvironment, potentially overcoming resistance to standard checkpoint inhibition in patients who have failed first-line treatments. The NMN component used in clinical trials is specifically identified as NMN12000 manufactured by GeneHarbor.

Other names

immunotherapy-Sichuan University-non-small cell lung cancerNMN + radiotherapy + PD-1 inhibitorNMN combined with radioimmunotherapyNMN12000 GeneHarbor + Radiotherapy + PD-1 inhibitor